Vol. 3 No. 9 (2023)
Reimbursement Reviews

Trastuzumab Deruxtecan (Enhertu)

Published September 11, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses trastuzumab deruxtecan (Enhertu),100 mg, powder for solution for IV infusion.
  • Indication: For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH−) breast cancer who have received at least 1 prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; patients with HR-positive breast cancer should have received at least 1 line of endocrine therapy and be no longer considered for endocrine therapy.